Innate Immunity Stimulation Via TLR9 in Early AD

This study tests a treatment that activates part of the immune system (via a receptor called TLR9) to see if it can slow down Alzheimer's disease in its early stages — either as mild cognitive impairment or mild dementia. **You may be eligible if...** - You are between 65 and 85 years old - You have been diagnosed with mild cognitive impairment or mild Alzheimer's dementia - Your Montreal Cognitive Assessment (MoCA) score is 17 or higher - You have had a positive amyloid PET scan (a brain scan showing Alzheimer's-related plaques) within the past year - You have a reliable study partner (family member, friend, or caregiver) who can accompany or contact you **You may NOT be eligible if...** - You have a history of psychiatric illness (e.g., hallucinations, major depression, suicidal thoughts) that could interfere with the study - You have autoimmune disorders, severe asthma, or major infections - You take corticosteroids or immune-suppressing drugs - You have had a stroke, TIA, or seizures in the past 12 months - You have another neurological condition contributing to memory problems - You are currently taking blood thinners or certain CYP1A2 enzyme-interacting drugs Talk to your doctor to see if this trial is right for you.